These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16823907)

  • 1. The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery.
    Davis SS
    Vaccine; 2006 Apr; 24 Suppl 2():S2-7-10. PubMed ID: 16823907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
    Jin Z; Gao S; Cui X; Sun D; Zhao K
    Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biodegradable polymer microspheres as vaccine adjuvants and delivery systems.
    Gupta RK; Chang AC; Siber GR
    Dev Biol Stand; 1998; 92():63-78. PubMed ID: 9554260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly-D,L-lactide-co-poly(ethylene glycol) microspheres as potential vaccine delivery systems.
    Zhou S; Liao X; Li X; Deng X; Li H
    J Control Release; 2003 Jan; 86(2-3):195-205. PubMed ID: 12526816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery.
    Payne LG; Jenkins SA; Andrianov A; Roberts BE
    Pharm Biotechnol; 1995; 6():473-93. PubMed ID: 7551232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymers.
    Garg NK; Mangal S; Khambete H; Tyagi RK
    Recent Pat Drug Deliv Formul; 2010 Jun; 4(2):114-28. PubMed ID: 20380624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery.
    Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M
    Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspects of the design and delivery of microparticles for vaccine applications.
    Jenkins PG; Coombes AG; Yeh MK; Thomas NW; Davis SS
    J Drug Target; 1995; 3(1):79-81. PubMed ID: 7655826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities.
    Sharma R; Agrawal U; Mody N; Vyas SP
    Biotechnol Adv; 2015; 33(1):64-79. PubMed ID: 25499178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microparticles as vaccine adjuvants and delivery systems.
    O'Hagan DT; Singh M
    Expert Rev Vaccines; 2003 Apr; 2(2):269-83. PubMed ID: 12899577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of chitosan microspheres for nasal delivery of vaccines.
    Kang ML; Cho CS; Yoo HS
    Biotechnol Adv; 2009; 27(6):857-865. PubMed ID: 19583998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response.
    Eldridge JH; Meulbroek JA; Staas JK; Tice TR; Gilley RM
    Adv Exp Med Biol; 1989; 251():191-202. PubMed ID: 2610110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens.
    Jiang W; Gupta RK; Deshpande MC; Schwendeman SP
    Adv Drug Deliv Rev; 2005 Jan; 57(3):391-410. PubMed ID: 15560948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers.
    Mishra N; Goyal AK; Tiwari S; Paliwal R; Paliwal SR; Vaidya B; Mangal S; Gupta M; Dube D; Mehta A; Vyas SP
    Expert Opin Ther Pat; 2010 May; 20(5):661-79. PubMed ID: 20345332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Particulate delivery systems for vaccines: what can we expect?
    Bramwell VW; Perrie Y
    J Pharm Pharmacol; 2006 Jun; 58(6):717-28. PubMed ID: 16734973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
    Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
    J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential of polyphosphazenes for delivery of vaccine antigens and immunotherapeutic agents.
    Eng NF; Garlapati S; Gerdts V; Potter A; Babiuk LA; Mutwiri GK
    Curr Drug Deliv; 2010 Jan; 7(1):13-20. PubMed ID: 19863483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in particulate-based vaccines.
    Perrie Y; Kirby D; Bramwell VW; Mohammed AR
    Recent Pat Drug Deliv Formul; 2007; 1(2):117-29. PubMed ID: 19075879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
    Vajdy M; Srivastava I; Polo J; Donnelly J; O'Hagan D; Singh M
    Immunol Cell Biol; 2004 Dec; 82(6):617-27. PubMed ID: 15550120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.